Trade bodies representing the European prescription and over-the-counter pharma sectors have issued a call to action to regulators, asking them to accelerate the adoption of electronic product ...

ANCA announced the launch of its InsertsPRO special inserts grinding package software product in September. According to the Australia-based CNC grinding technology company, InsertsPRO can support ...

Dear Dr. Roach: My primary care doctor has prescribed the medication Evenity for my osteoporosis. I have been on Fosamax for about three years, but my recent bone density scan went down slightly in ...

DEAR DR. ROACH: I have Type 2 diabetes. How often do I need to see my doctor? -- A.B. ANSWER: When a person is first diagnosed with Type 2 diabetes, a visit every three months is normally recommended.

Dear Dr. Roach: My doctor has prescribed the medication Evenity for my osteoporosis. I have been on Fosamax for about three years, but my recent bone density scan went down slightly. I am concerned ...

Dear Dr. Roach: My primary care doctor has prescribed the medication Evenity for my osteoporosis. I have been on Fosamax for about three years, but my recent bone density scan went down slightly in ...

DEAR DR. ROACH: My primary care doctor has prescribed the medication Evenity for my osteoporosis. I have been on Fosamax for about three years, but my recent bone density scan went down slightly in ...

University of Connecticut provides funding as a member of The Conversation US. A “black box” warning on a health product sounds pretty scary – maybe even more so when it’s suddenly being taken off the ...

Investing.com - Cantor Fitzgerald has reiterated its Neutral rating for Amgen (NASDAQ:AMGN) with a price target of $305.00, following the company’s commercial performance that exceeded expectations.

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...